Wells Fargo Sees Continued Upside for XenoPort (XNPT); Profile Suggests '829 Lower-Risk Than Early Indications

Wells Fargo maintains an 'Outperform' on XenoPort (NASDAQ: XNPT).

Analyst, Brian Abrahams, made comments after an in-depth (with company management) review of '829.

Abrahams said, "Our in-depth review of the preclinical data supports our view that '829 can effectively deliver MMF like BG12, and could ultimately have potential advantages of once-daily dosing and possibly better GI tolerability. We expect XNPT shares to continue to appreciate as '829 progresses through the clinic, and believe the reward-risk profile remains compelling."

For an analyst ratings summary and ratings history on XenoPort click here. For more ratings news on XenoPort click here.

Shares of XenoPort closed at $8.61 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
• Ryder Systems (R) PT Raised to $120 at Stephens
• Spotify (SPOT) PT Raised to $375 at Benchmark